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Abstract
Background: Periplakin (PPL) is a rod-shaped cytolinker protein thought to connect cellular adhesion junctional
complexes to cytoskeletal filaments. PPL serves as a structural component of the cornified envelope in the skin and
interacts with various types of proteins in cultured cells; its level decreases dramatically during tumorigenic
progression in human epithelial tissues. Despite these intriguing observations, the physiological roles of PPL,
especially in non-cutaneous tissues, are still largely unknown. Because we observed a marked fluctuation of PPL
expression in mouse liver in association with the bile acid receptor farnesoid X receptor (FXR) and cholestasis, we
sought to characterize the role of PPL in the liver and determine its contributions to the etiology and pathogenesis
of cholestasis.
Methods: Time- and context-dependent expression of PPL in various mouse models of hepatic and renal disorders
were examined by immunohistochemistry, western blotting, and quantitative real-time polymerase chain reactions.
Results: The hepatic expression of PPL was significantly decreased in Fxr−/− mice. In contrast, the expression was
dramatically increased during cholestasis, with massive PPL accumulation observed at the boundaries of
hepatocytes in wild-type mice. Interestingly, the hepatic accumulation of PPL resulting from cholestasis was
reversible. In addition, similar accumulation of PPL at cellular boundaries was found in epithelial cells around renal
tubules upon ureteral obstruction.
Conclusions: PPL may be involved in the temporal accommodation to fluid stasis in different tissues. Further
examination of the roles for PPL may lead to the discovery of a novel mechanism for cellular protection by
cytolinkers that is applicable to many tissues and in many contexts.
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Background
Hepatic bile production is required for the excretion of chol-
esterol and other waste products into the small intestine.
When bile flow is obstructed, biliary constituents re-enter
the liver and the systemic circulation, causing a variety of
local and systemic disorders, including jaundice, pruritus,
fatigue, osteoporosis, malabsorption, abnormal lipid metab-
olism, and immunosuppression [1]. In addition, protracted
cholestasis can elicit hepatic fibrosis, which could eventually
result in hepatic cirrhosis, hepatocarcinogenesis, and loss of
liver function [1]. Bile acids, the major constituents of bile,
play critical roles in many of these derangements
through their detergent-like properties or the activa-
tion of their receptors farnesoid X receptor (FXR,
NR1H4) and G-protein-coupled bile acid receptor 1
(GPBAR1, also known as Takeda G-protein-coupled
receptor 5) [2,3]. However, it is difficult to fully explain
the pathogenesis of cholestasis and concomitant disor-
ders by the direct actions of bile acids or the actions
mediated through the already known molecules con-
trolled by FXR and GPBAR1 alone; therefore, add-
itional regulatory molecules likely exist.
To discover the additional regulatory molecules engaged
in the pathogenesis of cholestasis and concomitant
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disorders, we sought previously undescribed molecules
associated with FXR and cholestasis, because evidence
exists that FXR critically influences the pathophysi-
ology of cholestasis in mouse models [4-6] and human
familial intrahepatic cholestasis type 1 (also known as
Byler's disease) [7]. Examination of hepatic gene ex-
pression profiles of Fxr null (Fxr−/−) and wild-type
mice [8], and comparison with the expression of se-
lected genes in a cholestatic mouse model (dietary cho-
lic acid [CA]-administration), revealed that periplakin
(PPL) is a unique protein central to FXR and cholestasis.
The basal expression level of Ppl mRNA was reduced in
the liver of Fxr−/− mice, whereas it was markedly increased
during cholestasis in wild-type mice. To our knowledge,
this is the first study that showed a relationship among
FXR, cholestasis, and PPL.
PPL is a member of the family of plakin/cytolinker
proteins, which connect cellular adhesion junctional
complexes to cytoskeletal filaments. Among the plakin
family proteins, PPL stands out for its size (the smallest
in the plakin family) and atypical domain structures
(lacks the actin-binding domain and proline-rich domain
that are conserved in most of plakin family proteins)
[9-11]. Historically, PPL was first discovered in the
1980s as one of the constituents of the cornified enve-
lope (CE), the outermost layer of the epidermis that pro-
vides a physical barrier for the skin [12]. In the 1990s,
PPL cDNA was isolated from keratinocytes [13,14].
Since its initial identification, the role of PPL has been
studied primarily in the skin, despite its expression in
many other tissues [13-15]. During keratinocyte differen-
tiation into corneocytes, PPL forms a heterodimer with
another plakin, envoplakin (EVPL), and is covalently
cross-linked to the heterogeneous network of desmosomes
(macula adherens), keratin filaments, loricrin, involucrin
(IVL), small proline-rich proteins, and membrane
lipids via the enzymatic activities of transglutaminases
(TGases). These molecular changes result in flattening
and stacking of cornified cells to form the CE layer of
the epidermis [16].
Interestingly, the heterodimeric partner for PPL, EVPL, is
predominantly expressed in the skin, kidney, lung, and pros-
tate [15,17]. Thus, PPL has EVPL-independent functions in
other tissues, including the liver. Indeed, many in vitro stud-
ies have revealed that PPL may modulate the intracellular
cytoskeletal network through interaction with a number of
molecules other than EVPL, including vimentin, keratin 8
(K8), beaded filament structural component 2 (also known
as cytoskeletal protein 49 kDa), filensin, plectin, and collagen
type XVII (also known as bullous pemphigoid antigen 2)
[14,15,18,19]. PPL has also been shown to inhibit intracellu-
lar signal transduction through interaction with family A
(rhodopsin-like) G-protein-coupled receptors [20-22]. Inter-
actions between PPL and Akt (also known as protein kinase
B) and the intracellular tail of immunoglobulin G receptor
(FcγRI) have also been reported [23,24]. Thus, PPL may
serve not only as a structural component in cells but also as
a functional regulatory molecule in various tissues.
Recently, studies in cancer proteomics have revealed
that PPL expression is markedly reduced during the pro-
gression of human esophageal squamous cell carcinoma
[25,26]. This decreased expression of PPL, which closely
paralleled the progression of malignancy, was associated
with changes in the intracellular localization of PPL
from the cellular periphery to the inner cytosol [25]. A
similar reduction in PPL expression was also reported in
urothelial cells during the progression of bladder cancer
[27]. Despite these intriguing observations in previous
studies, Ppl null (Ppl−/−) mice did not exhibit an overt
phenotype under normal breeding conditions [28]. On the
other hand, Ivl/Evpl/Ppl triple-null mice exhibited defect-
ive epidermal barrier formation due to an abnormal as-
sembly of CE-layer components, suggesting the functional
redundancy in these 3 proteins in the skin [29].
Taken together, these studies suggest that PPL acts as
a structural component in the skin, interacts with vari-
ous types of proteins in vitro, and may be involved in
tumorigenic progression in human epithelial tissues;
however, the physiological roles for PPL, especially in
non-cutaneous tissues, including the liver, remain uncer-
tain. In this study, we examined the expression of PPL in
the liver of Fxr−/− mice and in various cholestatic mouse
models in detail. The clarified pattern of expression of
PPL in these mice suggested that PPL plays an import-
ant role in the temporal accommodation to cholestasis.
The possible roles for PPL in urinary stasis and tumori-
genesis are also discussed.
Methods
Animals
Two- to 3-month-old male C57BL/6JJcl mice (CLEA, Tokyo,
Japan) fed an NMF diet (Oriental Yeast, Tokyo, Japan) were
used for all experiments, unless otherwise specified. Fxr+/+
and Fxr−/− mice [8] were fed a Rodent NIH-31 Auto 18–4
diet (Zeigler Brothers, Gardner, PA, USA) and sacrificed at
2–3 months of age. Five-week-old male leptin-deficient gen-
etically obese ob/ob or the control +/+ mice (C57BL/
6JHamSlc-ob/ob or +/+; SLC, Hamamatsu, Japan) were used
after acclimation to the NMF diet for 2 weeks. All mice were
fed ad libitum and housed in a light- and temperature-
controlled room under specific-pathogen-free conditions.
Mice were euthanized by cervical dislocation at the end of
each treatment. All animal studies were approved by the
relevant animal care and use committees of Kyoto Univer-
sity, National Cancer Institute (NCI), and Pennsylvania State
University (PSU), and were carried out in accordance with
the Guide for the Care and Use of Laboratory Animals pub-
lished by the National Institutes of Health (NIH).
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Ppl null mice
Ivl/Evpl/Ppl triple-heterozygous null (Ivl+/−;Evpl+/−;
Ppl+/−) mice were produced by the mating of Ivl/Evpl/
Ppl triple-homozygous null (Ivl−/−/Evpl−/−/Ppl−/−)
mice [29] (kindly provided by Drs. Fiona Watt [Can-
cer Research UK], Jouni Uitto [Thomas Jefferson Uni-
versity], and John F. Klement [Thomas Jefferson
University]) with C57BL/6JJcl mice. All of the single-
homozygous null (Ivl−/−, Evpl−/−, and Ppl−/−) mice
used for the creation of the triple-homozygous null
mice had been backcrossed onto a C57BL/6 back-
ground in the different facilities at which they were
generated [29]. Triple-heterozygous null offspring
were further backcrossed onto the C57BL/6JJcl background
for 2 more generations to obtain Ppl single-heterozygous
null (Ppl+/− [Ivl+/+/Evpl+/+/Ppl+/−]) mice. Ppl+/+ and Ppl−/−
mice born from mating of Ppl+/− mice were used in this
study. These mice have been backcrossed a total of 3 times
onto the C57BL/6JJcl background.
Serum chemistry
Blood was collected by retro-orbital bleeding. The sera
were separated by centrifugation at 3000 rpm for 10
min. Serum total bile acid (T-BA) levels were deter-
mined using the Total Bile Acid Assay kit (Diazyme La-
boratories, Poway, CA, USA). Other parameters were
determined by Oriental Bioservice, Inc. (Kyoto, Japan).
Chronic dietary treatments
Mice were fed the control NMF diet or the same diet
supplemented with 0.1%, 0.25%, or 1% w/w CA (Sigma,
St. Louis, MO, USA) for 7 days. Sodium lauryl sulfate
(SDS; Nacalai Tesque, Kyoto, Japan) was administered in
drinking water at 0.1%, 0.25%, or 1% (w/v) for 7 days.
Fxr+/+ or Fxr−/− mice fed the Rodent NIH-31 Auto 18–4
diet were subjected to a dietary switch at the age of 2
months; control NMF or 1% CA/NMF diet was provided
for an additional 7 days.
Acute administration of bile acids and synthetic FXR
ligands
CA or GW4064 (Tocris, Ellisville, MO, USA) dissolved
in 1% Tween 80/1% methylcellulose or the correspond-
ing vehicle solutions was dosed twice orally at 0, 10, 100,
or 1000 mg/kg (12-h interval; first administration at
2000 and second administration at 0800). Mice were eu-
thanized 2 h after the second administration.
Serial administration of the high-fat diet (HFD) and the
CA-containing diet
Mice fed the NMF diet were administered a HFD
(#F3282; Bioserv, Frenchtown, NJ, USA) for 8 weeks.
The mice were then subjected to a dietary switch from
the HFD to the 1% CA-containing NMF or the control
NMF diet for an additional 7 days.
ConA treatment
Mice were given 20 mg/kg concanavalin A type IV
(ConA; Sigma) dissolved in saline or the volume-
matched vehicle solution by tail vein injection. Mice
were euthanized 8, 24, or 48 h after the injection.
CCl4 treatment
Two- to 3-month-old male C57BL/6 mice were injected
intraperitoneally with carbon tetrachloride (CCl4) at 1
mL/kg dissolved in corn oil [30]. For the short-term
treatment, mice were euthanized 24 or 48 h after the in-
jection. For long-term treatment, the mice were admin-
istered the same dose twice a week for 4 weeks. Control
mice were administered volume-matched corn oil.
ANIT treatment
α-Naphthylisothiocyanate (ANIT; Aldrich, Milwaukee,
WI, USA) at 50 mg/kg dissolved in olive oil or volume-
matched vehicle solution was orally administered after
overnight fasting. Mice were euthanized 48 h after the
administration.
Bile duct ligation (BDL) and unilateral ureteral obstruction
(UUO)
Mice were anesthetized by intraperitoneal injection of
Avertin. After midline laparotomy, the common bile
duct (for BDL) or right ureter (for UUO) was double-
ligated with 8–0 nylon or 4–0 silk suture, respectively.
Sham operations were carried out by the same proce-
dures in which the ligation was substituted by gentle
touching of the bile duct or ureter. Mice were sacrificed
2, 7, or 21 days after the surgery.
Immunohistochemistry
Sections (6 μm) from frozen tissues mounted in Tissue-
Tek O.C.T. compound (Sakura Finetek, Tokyo, Japan) were
attached to MAS-coated slide glasses (Matsunami Glass,
Osaka, Japan), fixed in methanol for 10 min at −20°C, and
permeabilized with 0.1% Triton X-100 in PBS for 5 min.
After blocking with 1% bovine serum albumin (BSA)/PBS
for 1 h, sections were incubated with primary antibodies
diluted in 1% BSA/PBS overnight at 4°C. The following
antibodies were used: anti-PPL (A301-005A; Bethyl La-
boratories, Montgomery, TX, USA), anti-keratin 19 (K19;
TROMAIII; Developmental Studies Hybridoma Bank,
Iowa, IA, USA), anti-zonula occludens-1 (ZO-1; sc-33725;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
multidrug-resistance protein (MDR; sc-8313; Santa Cruz
Biotechnology), anti-γ-catenin (γ-CTN; sc-30996; Santa
Cruz Biotechnology), anti-aquaporin 2 (AQP2; sc-9882;
Santa Cruz Biotechnology), and anti-K8 (ab14053; Abcam,
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Cambridge, MA, USA). Slides were washed with PBS 3
times and incubated with Alexa488- or Alexa594-
conjugated secondary antibodies (Molecular Probes,
Eugene, OR, USA) at room temperature for 1 h or 4°C
overnight. Slides were then washed with PBS, mounted
in Fluoromount (Diagnostic Biosystems, Pleasanton,
CA, USA), and examined using fluorescence micros-
copy (DMRBE; Leica Microsystems, Tokyo, Japan).
Staining patterns for PPL were confirmed using pep-
tide blocking (BP301-005; Bethyl Laboratories), an al-
ternative antibody (customized polyclonal antibody
raised against mouse PPL; MBL, Nagoya, Japan), and
Ppl−/− mice. Staining patterns for K19 were also con-
firmed by use of an alternative antibody (ab52625;
Abcam).
Western blots
Frozen tissues were homogenized in protein extraction
buffer (50 mM Tris–HCl, 5 mM EDTA, 2% SDS, 10%
glycerol, 10 mM NaF, 1 mM Na3VO4) supplemented
with Complete Protease Inhibitor Cocktail (Roche, In-
dianapolis, IN, USA) using a Physcotron (Microtec
Nition, Funabashi, Japan). Aliquots (15 μg) of samples
were separated on 5–20% polyacrylamide gradient gels,
transferred to a polyvinylidene difluoride membranes
(Immobilon-P; Millipore, Billerica, MA, USA), and hy-
bridized with primary antibodies diluted in Tris-buffered
saline containing 6% skim milk and 0.05% Tween-20
(6% skim milk/TBST) overnight at 4°C. Membranes
were washed with 0.05% Tween-20-containing Tris-
buffered saline (TBST) 3 times and hybridized with
horseradish peroxidase-conjugated secondary antibodies
diluted in 6% skim milk/TBST at room temperature for
1 h or 4°C overnight. After washing with TBST 3 times,
signals were detected by an ECL Plus western blotting
detection system (GE Healthcare, Chalfont St. Giles,
UK). The immunoblots for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were used as the loading controls.
The following antibodies were used: PPL (A301-005A;
Bethyl Laboratories), K19 (TROMAIII; Developmental
Studies Hybridoma Bank), ZO-1 (sc-33725; Santa Cruz
Biotechnology), γ-CTN (2309; Cell Signaling Technol-
ogy, Danvers, MA, USA), DSG1 (sc-2011; Santa Cruz
Biotechnology), K8 (ab14053; Abcam), K18 (ab32118;
Abcam), plectin (ab32528; Abcam), and GAPDH
(2118; Cell Signaling Technologiy). For PPL, K19, and
ZO-1, the results were confirmed by the use of alterna-
tive antibodies.
NCI oligo-cDNA microarray
Equal amounts of total RNA samples extracted from the
liver of 2- to 3-month-old male Fxr+/+ and Fxr−/− mice,
using TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA),
were pooled for each genotype. Amino-modified cDNAs
were synthesized from 20 μg of pooled RNAs by using a
SuperScript indirect cDNA labeling kit (Invitrogen) and
labeled with Cy3 or Cy5 fluorescent dyes (Amersham
Pharmacia, Piscataway, NJ, USA). Dye-coupled cDNAs
were hybridized to the NCI in-house printed oligo-DNA
spotted glass slides (Mouse Exotic Evidence Based
Oligonucleotide Set, Gene Expression Omnibus acces-
sion number GPL4200). The slides were analyzed using
a GenePix 4000A dual-laser scanning system and
GenePix Pro 3.0 (Axon Instruments, Foster City, CA,
USA). Datasets were further analyzed by the microarray
Database system provided by the Center for Information
Technology at the NIH.
Quantitative RT-PCR (qPCR)
Total RNA (1 μg) extracted using TRIZOL Reagent was
pretreated with DNaseI (Invitrogen) and reverse-
transcribed by Superscript III reverse transcriptase
(Invitrogen) and primer p(dT)15 (Roche). Real-time PCR
was performed using an ABS 7300 sequence detection
system or StepOnePlus real-time PCR system (Applied
Biosystems, Foster City, CA, USA) with RT2 Real-Time
SYBR Green/Rox PCR master mix (SuperArray Biosci-
ences, Frederick, MD, USA) according to the manufac-
turer’s instruction. The real-time PCR conditions were
95°C for 10 min, followed by 40 cycles of 95°C for 15 s
and 60°C for 1 min. Absence of primer-dimers were
confirmed after reactions by melting curve analysis and
agarose gel electrophoresis. Relative expression levels
were determined by the ΔΔCt method using Gapdh or
36b4 mRNA (for ob/ob mice) levels as internal controls.
These control primers yielded constant values over the
treatments in the same tissues or cells.
Mouse primary hepatocytes
Mice were anesthetized with 0.5% sodium pentobarbital,
and livers were digested with a 2-step perfusion method
using liver perfusion and digestion media (Invitrogen)
delivered through the portal vein. Recovered cells were
washed 3 times with plating medium (Dulbecco’s modi-
fied Eagle medium supplemented with 5% fetal bovine
serum and penicillin-streptomycin) and resuspended in
the same medium. The live cells were seeded onto colla-
gen IV-coated 6-well plates (BD, Franklin Lakes, NJ,
USA) at 3.5 × 105 cells per well. Three hours after the
seeding, the medium was replaced with serum-free
medium (Medium199 supplemented with 0.1 μM dexa-
methasone, 0.1 μM insulin, and 0.1 μM T3) containing
bile acids or synthetic FXR ligand at various concentra-
tions. Bile acids (CA, chenodeoxycholic acid [CDCA],
deoxycholic acid [DCA], and lithocholic acid [LCA];
all from Sigma) and GW4064 were dissolved in di-
methyl sulfoxide (DMSO) and used at 0.1% final
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DMSO concentration in culture. The cells were harvested
20 h after ligand treatment.
Statistical analysis
Datasets were evaluated by 2-tailed unpaired t test,
Mann–Whitney U test, Steel’s test, or one-way analysis
of variance (ANOVA) with post hoc tests (Dunnett’s or
Bonferroni’s test) for statistical significance using Prism
5 (GraphPad Software, San Diego, CA, USA) and
MEPHAS (http://www.gen-info.osaka-u.ac.jp). P values
less than 0.05 were considered significant.
Results
Ppl mRNA expression was reduced in the liver of Fxr−/−
mice and markedly increased during cholestasis in
wild-type mice
Hepatic gene expression profiles of Fxr+/+ and Fxr−/−
mice were compared by cDNA microarray to identify
genes constitutively regulated by FXR in the liver. Among
the genes that appeared to be regulated by FXR, we fo-
cused on the gene encoding PPL, a plakin/cytolinker pro-
tein. Hepatic Ppl mRNA expression was considerably
reduced in Fxr−/− mice (8-fold). The reduction was con-
firmed by qPCR analysis. Indeed, expression level of Ppl
mRNA in the liver of Fxr−/− mice was typically lower than
that in the liver of Fxr+/+ mice (Figure 1A). To our know-
ledge, this is the first molecule in this family whose ex-
pression is associated with FXR. Expression of PPL during
cholestasis induced by the administration of CA through
the diet (0.1%–1% for 7 days) was also evaluated in the
liver of wild-type mice. PPL expression was markedly in-
creased in a dose-dependent manner at both the mRNA
and protein levels in response to dietary CA (Figure 1B,
left). Expression of the cholesterol 7α-hydroxylase gene
(cytochrome P450 7a1 [Cyp7a1]) was suppressed even at
the lowest concentration of dietary CA, confirming activa-
tion of FXR (Figure 1B, right). Interestingly, the CA-
dependent induction of Ppl mRNA expression was highly
tissue selective. Among the tissues examined, including
those directly or indirectly exposed to dietary CA, the in-
duction was particularly prominent in the liver, suggesting
an important role for PPL in the liver (Figure 1C). The
regulation of Ppl mRNA expression in the liver, following
CA feeding, was unique for its robustness, as compared to
other plakins and representative components of cytoskel-
eton and junctional complexes (Figure 1D).
PPL was localized to the cholangiocytes and the
boundaries of hepatocytes in normal liver
Next, we determined the localization of PPL in the liver of
wild-type mice by immunohistochemical analysis. The
highest expression of PPL was detected in bile duct epithelial
cells co-expressing K19, a cholangiocyte marker (Figure 2A).
PPL was also detected at the boundaries of hepatocytes and
overlapped with the tight junction protein ZO-1, a marker
for the bile canalicular membrane (Figure 2B). Faint expres-
sion was also noted at cellular borders lacking ZO-1 staining
(Figure 2B, arrowheads). In contrast to PPL, the bile canalic-
ular MDR (P-glycoproteins) were almost exclusively found
in areas surrounded by ZO-1 (Figure 2C). Thus, PPL local-
izes not only near the bile canaliculi but also near other cel-
lular boundaries of hepatocytes. The expression of PPL
partially overlapped with that of the desmosomal protein γ-
CTN (Figure 2D). Similar partially overlapping expression of
PPL with desmosomal protein has also been reported in cul-
tured keratinocytes [13]. Importantly, PPL expression was
undetectable by immunohistochemical analysis in Ppl−/−
mice, thus demonstrating antibody specificity (Figure 2E). In
line with these results, human PPL mRNA expression was
also found to be high in a cholangiocyte-derived cell line
(HuH7), considerably lower in a hepatocyte-derived cell line
(HepG2), and almost undetectable in a hepatic stellate cell-
derived cell line (LX-2) (data not shown).
PPL accumulated at the boundaries of hepatocytes
during dietary CA-induced cholestasis
The expression of PPL during dietary CA-induced chole-
stasis was determined by immunohistochemical examin-
ation in wild-type mice. The immunoreactive PPL
expression was not increased in mice fed the lowest con-
centration of CA (0.1%), while it slightly increased in
mice fed 0.25% CA (data not shown). In contrast, a
striking increase in PPL expression was found in mice
fed the highest concentration of CA (1%; Figure 3A).
The increase was primarily observed at the cellular
boundaries of hepatocytes. PPL expression was primarily
increased in ZO-1-positive locations; however, its expres-
sion was also increased in ZO-1-negative sites (Figure 3B,
left). Thus, in response to dietary CA, PPL appeared to
form an impressive web-like structure throughout the en-
tire liver (Figure 3A, right). This type of distribution was
reminiscent of a similar reticular localization pattern for
PPL reported in epithelial tissues, including the epidermis,
cervix uteri, and esophagus, under normal conditions
[13,25]. PPL expression partially overlapped with that of
γ-CTN following dietary CA, similar to what was ob-
served in the basal state (Figure 3B, right). Importantly,
the immunoreactivity of PPL was completely abolished in
CA-fed Ppl−/− mice (Figure 3C). The marked accumula-
tion of protein after CA feeding was selective to PPL and
was not observed for other structural molecules, including
plakin, junctional protein, and cytoskeletal components
examined (Figure 3D).
When the diet was switched back to the normal diet
after the induction of cholestasis by the administration
of dietary CA for 7 days (Figure 4A), the levels of
serum markers indicative of cholestasis, i.e., total bili-
rubin (T-Bil) and total bile acids (T-BA), and those of
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markers for hepatocellular injury, i.e., alanine amino-
transferase (ALT) and aspartate aminotransferase
(AST), rapidly declined to the normal range within 3
days (Figure 4B). Under these conditions, the amount
of accumulated PPL protein subsequently decreased
(Figure 4C). Thus, the hepatic modulation of PPL was
reversible, suggesting that the covalent irreversible
crosslinking of PPL typically found in the skin and me-
diated by TGases did not function in the livers of these
mice. In contrast to the time course for the serum
markers, the decrease of accumulated PPL in the liver
occurred more slowly after the reinstatement of the
diet, manifesting as a complete reversion to basal levels
after 2 weeks (Figure 4B and C).
Dietary CA-induced accumulation of PPL was attenuated
in the liver of Fxr−/− mice
The effect of CA feeding on PPL expression was investi-
gated in the liver of Fxr+/+ and Fxr−/− mice. PPL markedly
accumulated at the periphery of hepatocytes in Fxr+/+
mice throughout the liver after CA feeding (Figure 5A,
upper right). In contrast, the accumulation of PPL by the
same treatment was significantly attenuated in Fxr−/− mice
(Figure 5A, lower right). Both western blotting and qPCR
analyses detected increased PPL and Ppl mRNA expres-
sion, respectively, even in Fxr−/− mice fed 1% CA, albeit
the degree of increase was lower than that in Fxr+/+ mice
(Figure 5B).
Because Fxr−/− mice spontaneously develop fatty liver
[8], we hypothesized that attenuated induction of hepatic
PPL expression in Fxr−/− mice might be derived from ex-
cessive fat deposition. To examine this hypothesis, we
created an obese mouse model with fatty liver by feeding
wild-type mice a HFD for 2 months. These mice were
then administered a control or 1% CA-containing diet
for 7 days to examine the response to cholestasis. Similar
to the effects observed in Fxr−/− mice, the induction of
PPL expression in response to CA feeding was suppressed
in obese mice (Figure 5C and D). Given the unaltered ex-
pression of FXR in the liver of HFD-fed mice (data not
shown), the attenuated induction of PPL expression in
obese mice seemed to be independent of FXR. Taken to-
gether, these data suggest that the impaired PPL accumu-
lation in Fxr−/− mice during cholestasis was not a direct
consequence of the loss of FXR, but rather resulted from
excess fat deposition in the liver.
PPL expression was not directly regulated by FXR
To examine the relationship between FXR and PPL ex-
pression in more detail, we administered CA or the syn-
thetic FXR ligand GW4064 acutely to wild-type mice. In
contrast to chronic administration (Figure 1B), short-term
(14 h) treatment with either CA or GW4064 did not cause
an increase in hepatic PPL expression (Figure 5E, upper)
despite clear evidence of FXR activation as shown by sup-
pression of Cyp7a1 mRNA expression (Figure 5E, lower).
These results suggest that hepatic PPL induction was not
directly mediated through activation of FXR. The effect of
FXR ligands on Ppl mRNA expression was also examined
in vitro using primary mouse hepatocytes. Although ex-
pression of the FXR target gene small heterodimer partner
(Shp) was highly induced by bile acids and GW4064, par-
ticularly at higher concentrations (Figure 5F, lower), Ppl
mRNA expression was only modestly increased by the
same treatment in mouse primary hepatocytes (Figure 5F,
upper). Ppl mRNA was even decreased by treatment with
10 μM GW4064. Thus, robust induction of PPL expres-
sion by bile acids required chronic treatment in vivo,
and the conditions required for this type of regulation
were not fully emulated by cultured primary mouse
hepatocytes.
PPL accumulation was associated with cholestatic injury
One of the most distinctive physiological alterations fol-
lowing CA feeding is hepatocellular injury [31,32]. To
evaluate the effects of hepatocellular injury on PPL ex-
pression, we broadly examined PPL expression in dam-
aged liver of selected mouse models. First, we examined
non-cholestatic models mimicked by a non-bile acid de-
tergent, SDS; a plant lectin, ConA; and an organic solv-
ent, CCl4. These models represent detergent-induced
(SDS), hyperactive T lymphocyte-mediated (ConA), and
(See figure on previous page.)
Figure 1 PPL expression in Fxr−/−and CA-fed cholestasis model mice. (A) Hepatic Ppl mRNA expression levels in Fxr+/+ and Fxr−/−mice. Seven
or 8 mice per group were examined. Circles and rectangles correspond to individual animals. Horizontal bars represent averages. (B) Hepatic Ppl
and Cyp7a1 mRNA expression levels in wild-type mice fed cholic acid (CA) for 7 days at the indicated doses. Five to 9 mice per group were
examined. The immunoblot for PPL is also shown. Equal amounts of protein from 5 mice were combined in each group for western blotting. The
immunoblot for GAPDH was used as the loading control. (C) Ppl mRNA expression in various tissues following CA feeding for 7 days. Bars for
each tissue are grayscaled as indicated (darkened from left to right, tongue to skin). Bars for the liver are flagged with a number sign (#). Four
samples per group were examined. (D) Hepatic mRNA expression of plakins, cell junction proteins, and intermediate filaments in wild-type mice
fed CA for 7 days. Five to 9 mice per group were examined. mRNA expression levels are represented as values normalized to Gapdh. The average
values in Fxr+/+ and control diet-fed mice are set as 1.0. Values represent mean ± SD. Dsg1/2/4, desmoglein-1/-2/-4; Dsc2, desmocollin-2; Dsp,
desmoplakin; Plec, plectin; Macf1, microtubule actin crosslinking factor-1; β/γ-Ctn, β/γ-catenin; Gjp1/2, gap junction protein-1/-2; E/N-Cad, E/N-cadherin;
Cldn1/2/3, claudin-1/-2/-3; Ocln, occludin; Zo-1, zonula occludens-1; JAM1, junctional adhesion molecule-1; K7/8/18/19, keratin 7/8/18/19. *, **, ***: P < 0.05,
0.01, and 0.001, respectively, by Mann–Whitney U test (A) or one-way ANOVA with Dunnett’s test (B and D [vs. 0%]).
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reactive oxygen species-mediated (CCl4) injuries [33,34].
Although slight differences were observed depending on
the doses and durations applied, all of these treatments
caused similar effects on PPL expression, with incremental
changes in mRNA; however, robust protein accumulation
was not detected (Table 1 and Figure 6A). Second, the ex-
pression of PPL was examined in models with chronic
damages from hepatic fibrosis or steatosis. CCl4 is a po-
tent inducer of hepatic fibrosis when administered chron-
ically [34]. After 4 weeks of CCl4 intoxication, severe
(See figure on previous page.)
Figure 2 Immunohistochemical localization of PPL in normal liver. (A) Representative images for the localization of PPL and K19 in normal
liver. PPL and K19 were double-stained by red and green fluorescence, respectively. Merged images are shown on the right. Scale bars: 100 μm
(upper) and 25 μm (lower). (B) PPL and ZO-1 were double-stained by red and green fluorescence, respectively. Merged images are shown on the
right. Arrowheads indicate PPL expression at ZO-1-negative sites. Scale bars: 100 μm (upper) and 25 μm (lower). (C) MDR and ZO-1 were double-
stained by red and green fluorescence, respectively. Merged images are shown on the right. Scale bar: 25 μm. (D) PPL and γ-catenin (γ-CTN) were
double-stained by red and green fluorescence, respectively. Merged images are shown on the right. Scale bar: 25 μm. (E) PPL and K19 were
double-stained by red and green fluorescence, respectively. Signals for PPL were absent in cholangiocytes and hepatocytes of Ppl−/− mice. Scale
bar: 100 μm. PV, portal vein; BD, bile duct.
Figure 3 Immunohistochemical localization of PPL in the cholestatic liver. (A) Representative images for the hepatic localization of PPL in
mice fed the control or 1% CA-containing diet for 7 days. PPL was detected by red fluorescence. Scale bar: 100 μm. (B) PPL and ZO-1 (left column),
or PPL and γ-CTN (right column), were double-stained by red and green fluorescence, respectively. Merged images are shown at the bottom.
Arrowheads indicate PPL expression at ZO-1-negative sites (left bottom). Scale bar: 25 μm. (C) PPL and K19 were double-stained by red and green
fluorescence, respectively. Signals for PPL were absent in cholangiocytes and hepatocytes of 1% CA-fed Ppl−/− mice. Scale bar: 100 μm. (D) Protein
abundance of the selected hepatic structural molecules in the liver of CA-fed mice at indicated doses for 7 days. Four mice per group were examined
by western blotting analysis. The immunoblots for GAPDH were used as the loading controls. PV, portal vein; CV, central vein.
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hepatic fibrosis accompanied by a substantial elevation in
serum ALT and AST levels was induced. However, a
marked increase in Ppl mRNA or robust accumulation of
PPL protein was not observed (Table 1 and Figure 6A).
Next, leptin-deficient genetically obese (ob/ob) mice were
used as a model for steatosis. While a slight increase in
Ppl mRNA expression was observed, robust accumulation
of PPL protein was not detected in this model (Table 1
and Figure 6A). Lastly, expression of PPL in cholestatic
mouse models was investigated using ANIT and BDL;
these approaches induce 2 distinct types of cholestasis,
cholangiocellular injury-derived (intrahepatic) and ob-
structive (extrahepatic) cholestasis, respectively [35,36].
Severe cholestasis was induced by both treatments, as
confirmed by serum T-BA and T-Bil levels (Table 1). Both
the increase in Ppl mRNA expression and the
Figure 4 PPL expression after recovery from dietary CA-induced cholestasis. (A) Dietary administration schedule. Seven weeks-old male
wild-type mice fed NMF diet were separated in two groups. One group (Recovery) was given the 1% CA-containing NMF diet for 1 week to
induce cholestasis; the diet was then replaced by the control NMF diet to resolve the cholestatic situations. The other group (Control) was given
the control NMF diet throughout the experiment. Mice were sacrificed in each group at the time points indicated by arrows. (B) The levels of the
serum markers for cholestasis (T-Bil and T-BA; left panel) and hepatocellular injury (ALT and AST; right panel) at each time point in control and recovery
groups. Values are shown by the symbols and colors as indicated in inlets. Averages from 5 mice are expressed with standard errors. (C) Hepatic PPL
expression examined by immunohistochemical and western blot analyses. Representative images resulting from immunohistochemical analysis are
shown for each group (upper). Five mice per group were examined for western blot analysis (lower). The immunoblot for GAPDH was used as the
loading control. Scale bar: 100 μm.
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accumulation of the PPL protein at cellular boundar-
ies were quite apparent in these models (Table 1 and
Figure 6A, B, and C). Notably, the accumulation of
PPL following BDL was observed as early as 2 days
post-ligation, suggesting a role for PPL in early response
to cholestasis (Figure 6D, E, and F). In addition, while bile
duct ligation significantly increased the amount of K19,
ANIT did not affect K19 expression, similar to dietary CA
(Figures 6B, C, and 3F).
Taken together, these results indicate that hepatic Ppl
mRNA expression could be elevated by several distinct
mediators of hepatocellular injury; however, robust
Figure 5 The effect of FXR ligands on PPL expression. (A) Representative images for hepatic PPL distribution in Fxr+/+ and Fxr−/− mice fed the
control or 1% CA-containing diet for 7 days. Scale bar: 100 μm. (B) Hepatic mRNA and protein expression of PPL in Fxr+/+ and Fxr−/− mice under
normal and CA-fed conditions. Five mice per group were examined. The immunoblot for GAPDH was used as the loading control. (C) Hepatic
PPL distribution in NMF-fed (lean) or HFD-fed (obese) mice following CA feeding. Scale bar: 100 μm. (D) Hepatic mRNA and protein expression of
PPL in lean and obese mice following CA feeding. Four mice per group were examined. The immunoblot for GAPDH was used as the loading
control. (E) Hepatic Ppl and Cyp7a1 mRNA expression levels in mice acutely administered CA or GW4064 via oral gavage at the indicated doses.
Five mice per group were examined. The immunoblot for PPL is also shown. Equal amounts of protein from 5 mice were combined in each
group for western blotting. The immunoblots for GAPDH were used as the loading controls. (F) Ppl and Shp mRNA expression levels in mouse
primary hepatocytes administered FXR ligands at the indicated concentrations. Four samples per group were examined. (−), untreated; Veh,
vehicle. mRNA expression levels are normalized to Gapdh. The average values in control diet-fed Fxr+/+ mice (B), lean mice (D), or vehicle-treated
groups (E and F), were set to 1.0. Values represent mean ± SD. *, **, ***, ****: P < 0.05, 0.01, 0.001, and 0.0001, respectively, by one-way ANOVA
with post hoc tests (Bonferroni’s test [B and D] or Dunnett’s test [F; vs. Veh]), Steel’s test (E [CA vs. Veh]), or unpaired t test (E [GW4064 vs. Veh]).
ND, not determined.
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induction at the protein level and accumulation at hepa-
tocellular boundaries occurred only after treatments that
cause cholestasis. Because many of the employed treat-
ments (ConA [8 h and 24 h], CCl4 [24 h and 48 h]), elic-
ited greater hepatic damage than 1% CA feeding
(Table 1), it was evident that the severity of hepatocellu-
lar injury was not the key determinant for the degree of
PPL accumulation; rather, the difference between chole-
static and non-cholestatic responses was of prime
importance.
PPL accumulated in renal tubular epithelial cells following
ureteral obstruction
To discriminate between the effects of the flooded bile
in the liver and those mediated by fluid obstruction in
general on PPL accumulation, we investigated renal PPL
expression during ureteral obstruction. PPL expression
in tubular epithelial cells in the renal cortex was markedly
increased in wild-type mice after ureteral obstruction for
7 days (Figure 7A and B). Similar to its accumulation in
hepatocytes, PPL was condensed at the cellular periphery
Table 1 PPL expression in experimental mouse models of hepatic injury
Triggers/Treatments Serum markers PPL
N† ALT (IU/L) AST (IU/L) T-Bil (mg/L) N‡ T-BA (μmol/L) N§ mRNA (qPCR) Protein (IHC*)
Dietary bile acid CA 0% 5 25±2 79±16 0.06±0.01 5 6.4±1.3 8 1.0±0.30 -
(7 d) 0.1% 5 45±9 107±13 0.06±0.01 5 11±4.3 7 1.7±0.87 -
0.25% 4 494±133 496±192 0.08±0.01 4 49±21 8 3.8±1.7 +
1.0% 5 428±186 315±120 0.89±0.43 5 460±65 8 9.5±4.1 ++++
Dietary detergent SDS 0% 5 33±3 75±12 0.05±0.01 5 6.3±3.1 5 1.0±0.57 -
(7 d) 0.1% 5 36±11 94±21 0.05±0.01 5 7.4±1.9 5 1.6±0.52 -
0.25% 5 32±5 117±23 0.06±0.01 5 8.8±2.4 4 1.7±0.66 -
1.0% 5 43±6 219±23 0.11±0.02 5 6.0±1.5 4 4.0±2.1 -
Acute hepatitis ConA Initial 4 33±1 107±10 0.08±0.01 4 3.1±1.3 4 1.0±0.20 -
(T cell-mediated) Veh 8 h 6 34±8 111±25 0.08±0.01 6 3.6±0.76 6 2.8±0.73 -
ConA 8 h 5 4927±3414 3181±2121 0.55±0.10 5 27±14 5 3.5±1.9 -
Veh 24 h 5 38±8 120±30 0.08±0.01 5 6.2±2.6 5 1.3±0.76 -
ConA 24 h 4 6866±813 6296±1025 0.23±0.06 4 42±9.1 4 6.7±3.4 +
Veh 48 h 5 35±6 110±28 0.05±0.01 5 3.2±0.78 4 1.6±0.23 -
ConA 48 h 8 376±201 423±124 0.10±0.02 8 14±6.8 8 2.9±0.61 +
Acute hepatitis CCl4 Veh 24 h 5 42±25 169±43 0.08±0.02 5 2.4±0.53 5 1.0±0.23 -
(ROS-mediated) CCl4 24 h 5 7774±2745 5235±1775 0.21±0.03 5 69±15 5 2.0±0.94 -
Veh 48 h 5 36±3 117±32 0.06±0.01 5 3.3±0.90 5 1.1±0.42 -
CCl4 48 h 5 11376±2964 7140±2472 0.19±0.03 5 120±20 5 7.6±1.8 +
Hepatic fibrosis CCl4 Veh 4 w 5 49±19 173±50 0.06±0.02 5 2.7±0.30 5 1.0±0.69 -
CCl4 4 w 5 346±144 322±39 0.09±0.02 5 9.8±1.5 5 1.4±0.30 +
Hepatic steatosis ob/ob +/+ 5 23±3 71±8 0.04±0.01 5 2.2±1.5 5 1.0±0.48 -
ob/cob 5 145±44 139±27 0.04±0.01 5 11±6.2 5 1.7±0.43 -
Acute cholestasis ANIT Veh 48 h 7 36±8 115±42 0.04±0.01 4 5.2±1.1 4 1.0±0.54 -
(Intrahepatic) ANIT 48 h 5 1807±811 2572±1848 1.2±0.88 5 710±300 5 25±5.0 ++++
Chronic cholestasis BDL No treat 5 22±4 77±6 0.07±0.03 3 4.5±2.4 5 1.0±0.33 -
(Obstructive) Sham 7d 5 26±4 82±10 0.05±0.01 5 5.1±3.2 5 0.60±0.29 -
BDL 7d 5 880±316 936±339 12.4±3.6 5 800±210 5 12±1.9 +++++
Sham 21d 5 27±7 99±27 0.05±0.01 5 6.0±4.0 5 0.99±0.42 -
BDL 21d 5 604±378 1174±757 10.3±2.5 5 1100±480 5 5.1±1.7 +++++
PPL expression in Fxr−/−and CA-fed cholestasis model mice.PPL accumulation at hepatocellular boundaries is expressed as the degree of enhancement of
immunohistochemical staining from the basal status as shown in Figure 6C. At least 4 mice per group were used for immunohistochemistry (IHC) and blind tests
by multiple investigators. Western blot analysis was used for confirmation. †Number of mice used for the determination of serum ALT, AST, and T-Bil levels;
‡number of mice used for T-BA; §number of mice used for qPCR. Values represent mean ± SD. ALT, alanine aminotransferase; ANIT, α-naphthylisothiocyanate; AST,
aspartate aminotransferase; BDL, bile duct ligation; T-BA, total bile acids; T-Bil, total bilirubin.
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Figure 6 The hepatic accumulation of PPL was highly associated with cholestasis. (A) Representative images for the hepatic accumulation of
PPL under different types of hepatitis mediated by the indicated triggers. Protein abundance of PPL measured by western blotting is also shown at
the bottom. Equal amounts of protein from 5 mice were combined in each group for western blotting. The immunoblot for GAPDH was used as the
loading control. Scale bar: 100 μm. (B) Hepatic PPL expression in vehicle- or ANIT-treated mice examined by immunohistochemical and western
blotting analyses. Protein abundances of K19 and ZO-1 examined by western blotting are also shown. Four or 5 mice per group were examined. The
immunoblots for GAPDH were used as the loading controls. Scale bar: 100 μm. (C) Hepatic PPL expression levels in bile duct-ligated (BDL, for indicated
durations) or sham-operated mice examined by immunohistochemical and western blotting analyses. Immunoblots for K19 and ZO-1 are also shown.
Five mice per group were examined. The immunoblots for GAPDH were used as the loading controls. Scale bar: 100 μm. (D) Time course of the
induction of hepatic Ppl mRNA expression in wild-type mice after bile duct ligation. Five to 10 mice per group were examined. mRNA expression
levels are normalized to Gapdh and are expressed as mean ± SD. The average value in the liver of untreated mice was set to 1.0. ***: P < 0.001 by
one-way ANOVA with Dunnett’s test (vs. untreated). (E) Time course of the hepatic PPL accumulation in bile duct-ligated mice examined by western
blotting analysis. Three mice per group were examined. The immunoblot for GAPDH was used as the loading control. (F) Representative images for
the time course of the hepatic PPL accumulation in bile duct-ligated mice examined by immunohistochemical analysis. Scale bar: 100 μm.
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(Figure 7B). Weaker induction was also noted at
Bowman’s capsule and contiguous proximal tubules at the
urinary pole of the corpuscle (Figure 7B, arrow). In con-
trast to the observation in the liver, robust accumulation
in the renal cortex was not recognizable by day 2 of the
obstruction (data not shown). The expression of PPL par-
tially overlapped with that of the collecting duct marker
AQP2 (Figure 7C) [37] and almost completely overlapped
with that of K19 in the renal cortex (Figure 7D); K19 is
predominantly expressed in the distal tubules and
collecting ducts of normal kidneys [38]. The expression of
PPL and K19 in the renal cortex occurred synchronously,
i.e., very low at the basal state and markedly increased
after ureteral obstruction (Figure 7D). A similar synchron-
ous increase of PPL and K19 was also observed in
cholestatic mice produced by BDL but not in other
models (i.e., CA feeding and ANIT intoxication; Fig-
ures 3F, 6B, and 6C). Thus, a cooperative function of PPL
and K19 may be observed in severely obstructed tissues.
The specificity of the immunohistochemical signal for
PPL was also confirmed in the kidney by using Ppl−/−
mice (Figure 7E).
Discussion
The current study demonstrated that a plakin family
cytolinker protein, PPL, whose molecular function
in vivo is still largely unknown, dramatically accumu-
lated in the cholestatic liver and obstructed kidney. The
hepatic accumulation of PPL was observed as an early
response to cholestasis; it was detectable as early as 2
Figure 7 Induction of the renal accumulation of PPL near the tubules of obstructed kidneys. (A) Representative images for the localization
of PPL in the cortex, outer medulla, and inner medulla of the contralateral (unobstructed) and obstructed kidneys. Results from wild-type mice
subjected to unilateral ureteral obstruction for 7 days are shown. PPL was detected by red fluorescence. Scale bar: 100 μm. (B) Magnified images
for PPL localization in the cortex and medulla of obstructed kidneys. The arrow indicates the urinary pole of the corpuscle. Scale bar: 25 μm. (C)
Partial overlapping of the localization of PPL and aquaporin 2 (AQP2) in the cortex and outer medulla of contralateral (Cont.) and obstructed
(Obst.) kidneys. PPL and AQP2 were double-stained by red and green fluorescence, respectively. Merged images are shown on the right. Scale
bar: 100 μm. (D) Partial overlapping of the localization of PPL and K19 in the cortex and outer medulla of contralateral and obstructed kidneys.
PPL and K19 were double-stained by red and green fluorescence, respectively. Scale Bar: 100 μm. (E) Immunohistochemical signals for PPL were
absent in the obstructed renal cortex of Ppl−/− mice. Scale bar: 100 μm. Asterisks in each panel indicate glomeruli.
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days post-BDL and even in a milder cholestatic mouse
model lacking the hallmarks of severe obstructive injury
(i.e., dietary CA administration). On the other hand, the
accumulation of PPL persisted more than 1 week after
the removal of cholestatic agents, while recovery from
hepatocellular injury was observed within a few days.
This rapid-onset and long-lasting mode of PPL accumu-
lation suggests the potential involvement of PPL in liver
protection and repair. In addition, the robust accumula-
tion of PPL found at the periphery of renal tubules fol-
lowing urinary obstruction suggests a similar role for
this protein in the liver and kidney.
Importantly, in contrast to the irreversible incorpor-
ation of PPL into the CE layer of epidermis through co-
valent crosslinking by TGases, the accumulation of PPL
at the cellular periphery of hepatocytes occurred in a re-
versible manner, suggesting a different mode of usage
for PPL in cutaneous and non-cutaneous tissues. Intri-
guingly, other studies recently revealed that the distribu-
tion of PPL at cellular peripheries, which was observed
in normal epithelial tissues, is markedly reduced during
tumorigenic progression in the esophagus [25]. Thus,
the peri-plasma membrane distribution of PPL may be
important for protecting cells not only from the dam-
ages caused by fluid obstruction, but also from tumori-
genesis. It is tempting to assume that PPL functions
through a bidirectional shift between the basal and accu-
mulated state at cellular boundaries, depending on the
timing and context in different epithelial tissues. Apart
from indicating the physiological roles for PPL, our re-
sults suggest that the intracellular accumulation of PPL
might serve as a novel biomarker for fluid obstruction,
because its abundance and intracellular localization
clearly reflect the presence of the pathological state.
The precise molecular mechanism underlying the initi-
ation of PPL accumulation during cholestasis is not fully
understood. One possibility is that the accumulation of
PPL is triggered by biliary constituents building up in
the liver. However, because short-term administration of
CA failed to elicit robust PPL expression both in vivo
and in vitro, CA may not be an immediate trigger. Other
factors that accumulate in the cholestatic liver and/or
the physiological alterations accompanying cholestasis
may also be important. Notably, the mRNA and protein
levels of PPL were not completely paralleled (Table 1),
suggesting the importance of post-transcriptional regula-
tions of PPL expression in response to cholestasis. The
marked accumulation of PPL in the renal cortex during
urinary stasis suggests that structural and/or physio-
logical alterations common to the liver and kidney, such
as increased hydrostatic pressure or mechanical stretch,
might be of importance for the accumulation of PPL. In-
deed, recent studies revealed that the expression of PPL
can be highly induced by biomechanical stress in
saphenous vein coronary artery bypass grafts and in cul-
tured cells grown under a cyclic stretch [39]. However,
possibilities still remain that the increase in intra-tissue
or systemic humoral factor(s) such as the immunological
factors, would be the common trigger for PPL accumu-
lation in the liver and kidney.
Despite the fact that our study was based on micro-
array analyses of Fxr−/− mice, the regulation of PPL ex-
pression via FXR appeared to be indirect. Indeed,
hepatic Ppl mRNA expression was lower in Fxr−/− mice
at the basal state, and the accumulation of PPL following
bile acid feeding was clearly attenuated in the liver of
Fxr−/− mice. However, several lines of evidence support
the indirect regulation of PPL expression through FXR:
(i) acute administration of synthetic FXR ligand did not
induce Ppl mRNA expression in vivo or in vitro; (ii) the
attenuated accumulation of PPL during cholestasis in
the liver of Fxr−/− mice appeared to be secondary to fat
deposition; and (iii) the proximal promoter region of
mouse Ppl gene, that was deduced from the human PPL
gene [40], does not contain typical FXRE (data not
shown).
Based on recent results of chromatin immunoprecipi-
tation coupled with genome-wide sequencing (ChIP-
seq), there is a potent FXR-binding site 4.3 kb upstream
from the transcription start site of the mouse Ppl gene
[41,42]. We examined whether this site was a functional
FXR response element (FXRE) by using conventional
ChIP assays in the liver of mice treated with FXR ligands
(CA and GW4064). Although basal binding of FXR to
this site was confirmed, increased binding of FXR to the
same element was not observed. In clear contrast, bind-
ing of FXR to the canonical FXRE in the Shp promoter
was dramatically increased by FXR ligands (data not
shown). These results suggest that the potent FXR-
binding site found in the Ppl promoter is different from
the canonical FXRE. This unique element in the Ppl pro-
moter might be responsible for the enigmatic mode of
regulation of the hepatic PPL expression at least in a part.
Conclusions
In conclusion, PPL emerged as an intriguing unique
molecule that dramatically accumulated at the cellular
boundaries of hepatocytes and renal tubular epithelial
cells in response to biliary and urinary obstruction. Be-
cause a similar modal shift in PPL expression has also
been observed during tumorigenesis in epithelial tissues,
further examination of the role of PPL may lead to the
discovery of a novel mechanism for cellular protection
by cytolinkers that is applicable to many tissues and in
many contexts, including cholestasis and tumorigenesis.
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